OBJECTIVES The aim of this study was to assess the development of HTA in Turkey.   METHODS In this regard, organization structures of the Ministry of Health (MoH) and Social Security Institution (SSI) and presentations of first HTA meeting held in April 2014 have been analyzed. RESULTS There are three main HTA agencies in Turkey. One is under the payer institution called SSI. The HTA committee of SSI assesses all the new health technologies to define whether they will be reimbursed or not. In other words, this committee is the major decisive HTA committee. Other two HTA committees are under the MoH. One of these is under the General Directorate of Pharmaceuticals and Medical Devices. This committee assesses certain drugs which are specifically asked to be evaluated by the SSI, MoH or other Ministries. One of the projects completed by this committee is the evaluation of top 100 selling drugs according to the effect of price, regulation, market and qualitative characteristics of drugs. The second committee of the MoH is under the General Directorate of Health Research. This committee assesses more general issues like obesity, KOAH etc., instead of certain health technologies and publishes national reports. One of the reports published by this committee was the importance of obesity surgery in the treatment of obesity. In addition to all these three committees, HTA studies also being carried out by a MoH hospital called Ankara Numune Training and Research Hospital (ANHTA). They have been working on hospital based HTA. CONCLUSIONS Despite valuable studies being conducted as stated above, HTA is still in its infancy in Turkey and compared to other EU countries like Germany, UK etc. there is not an autonomous HTA agency. There are more than one committee, working on different aspects of health technology assessment under the supervision of government.